Bill No. CS/CS/SB 1030 (2014)

	Amendment No.
	CHAMBER ACTION
	<u>Senate</u> <u>House</u>
1	Depresentative Costs offered the fallowing.
1 2	Representative Gaetz offered the following:
∠ 3	Amendment (with title amendment)
4	Remove everything after the enacting clause and insert:
- 5	Section 1. This act may be cited as the "Compassionate
6	
7	Section 2. Section 381.986, Florida Statutes, is created
, 8	
9	
10	(1) DEFINITIONSAs used in this section, the term:
11	(a) "Dispensing organization" means an organization
12	
13	
	329511

20011

Bill No. CS/CS/SB 1030 (2014)

Amendment No.

	Amendment NO.
14	(b) "Low-THC cannabis" means a plant of the genus
15	Cannabis, the dried flowers of which contain 0.8 percent or less
16	of tetrahydrocannabinol and more than 10 percent of cannabidiol
17	weight for weight; the seeds thereof; the resin extracted from
18	any part of such plant; or any compound, manufacture, salt,
19	derivative, mixture, or preparation of such plant or its seeds
20	or resin that is dispensed only from a dispensing organization.
21	(c) "Medical use" means administration of the ordered
22	amount of low-THC cannabis. The term does not include the
23	possession, use, or administration by smoking. The term also
24	does not include the transfer of low-THC cannabis to a person
25	other than the qualified patient for whom it was ordered or the
26	qualified patient's legal representative on behalf of the
27	qualified patient.
28	(d) "Qualified patient" means a resident of this state who
29	has been added to the compassionate use registry by a physician
30	licensed under chapter 458 or chapter 459 to receive low-THC
31	cannabis from a dispensing organization.
32	(e) "Smoking" means burning or igniting a substance and
33	inhaling the smoke. Smoking does not include the use of a
34	vaporizer.
35	(2) PHYSICIAN ORDERINGEffective January 1, 2015, a
36	physician licensed under chapter 458 or chapter 459 who has
37	examined and is treating a patient suffering from cancer or a
38	physical medical condition that chronically produces symptoms of
39	seizures or severe and persistent muscle spasms may order for
د 	329511
	5/1/2014 7.57 DM

Bill No. CS/CS/SB 1030 (2014)

Amendment No.

40	the patient's medical use low-THC cannabis to treat such
41	disease, disorder, or condition or to alleviate symptoms of such
42	disease, disorder, or condition, if no other satisfactory
43	alternative treatment options exist for that patient and all of
44	the following conditions apply:
45	(a) The patient is a permanent resident of this state.
46	(b) The physician determines that the risks of ordering
47	low-THC cannabis are reasonable in light of the potential
48	benefit for that patient. If a patient is younger than 18 years
49	of age, a second physician must concur with this determination,
50	and such determination must be documented in the patient's
51	medical record.
52	(c) The physician registers as the orderer of low-THC
53	cannabis for the named patient on the compassionate use registry
54	maintained by the department and updates the registry to reflect
55	the contents of the order. The physician shall deactivate the
56	patient's registration when treatment is discontinued.
57	(d) The physician maintains a patient treatment plan that
58	includes the dose, route of administration, planned duration,
59	and monitoring of the patient's symptoms and other indicators of
60	tolerance or reaction to the low-THC cannabis.
61	(e) The physician submits the patient treatment plan
62	quarterly to the University of Florida College of Pharmacy for
63	research on the safety and efficacy of low-THC cannabis on
64	patients.

329511

Bill No. CS/CS/SB 1030 (2014)

Amendment No.

	Allendhent No.
65	(f) The physician obtains the voluntary informed consent
66	of the patient or the patient's legal guardian to treatment with
67	low-THC cannabis after sufficiently explaining the current state
68	of knowledge in the medical community of the effectiveness of
69	treatment of the patient's condition with low-THC cannabis, the
70	medically acceptable alternatives, and the potential risks and
71	side effects.
72	(3) PENALTIES.—
73	(a) A physician commits a misdemeanor of the first degree,
74	punishable as provided in s. 775.082 or s. 775.083, if the
75	physician orders low-THC cannabis for a patient without a
76	reasonable belief that the patient is suffering from:
77	1. Cancer or a physical medical condition that chronically
78	produces symptoms of seizures or severe and persistent muscle
79	spasms that can be treated with low-THC cannabis; or
80	2. Symptoms of cancer or a physical medical condition that
81	chronically produces symptoms of seizures or severe and
82	persistent muscle spasms that can be alleviated with low-THC
83	cannabis.
84	(b) Any person who fraudulently represents that he or she
85	has cancer or a physical medical condition that chronically
86	produces symptoms of seizures or severe and persistent muscle
87	spasms to a physician for the purpose of being ordered low-THC
88	cannabis by such physician commits a misdemeanor of the first
89	degree, punishable as provided in s. 775.082 or s. 775.083.
90	(4) PHYSICIAN EDUCATION

329511

Bill No. CS/CS/SB 1030 (2014)

Amendment No.

	Allendinent No.
91	(a) Before ordering low-THC cannabis for use by a patient
92	in this state, the appropriate board shall require the ordering
93	physician licensed under chapter 458 or chapter 459 to
94	successfully complete an 8-hour course and subsequent
95	examination offered by the Florida Medical Association or the
96	Florida Osteopathic Medical Association that encompasses the
97	clinical indications for the appropriate use of low-THC
98	cannabis, the appropriate delivery mechanisms, the
99	contraindications for such use, as well as the relevant state
100	and federal laws governing the ordering, dispensing, and
101	possessing of this substance. The first course and examination
102	shall be presented by October 1, 2014, and shall be administered
103	at least annually thereafter. Successful completion of the
104	course may be used by a physician to satisfy 8 hours of the
105	continuing medical education requirements required by his or her
106	respective board for licensure renewal. This course may be
107	offered in a distance learning format.
108	(b) The appropriate board shall require the medical
109	director of each dispensing organization approved under
110	subsection (5) to successfully complete a 2-hour course and
111	subsequent examination offered by the Florida Medical
112	Association or the Florida Osteopathic Medical Association that
113	encompasses appropriate safety procedures and knowledge of low-
114	THC cannabis.
115	(c) Successful completion of the course and examination
116	specified in paragraph (a) is required for every physician who
د ا	29511
3	

Bill No. CS/CS/SB 1030 (2014)

Amendment No.

	Amendment No.
117	orders low-THC cannabis each time such physician renews his or
118	her license. In addition, successful completion of the course
119	and examination specified in paragraph (b) is required for the
120	medical director of each dispensing organization each time such
121	physician renews his or her license.
122	(d) A physician who fails to comply with this subsection
123	and who orders low-THC cannabis may be subject to disciplinary
124	action under the applicable practice act and under s.
125	456.072(1)(k).
126	(5) DUTIES OF THE DEPARTMENTBy January 1, 2015, the
127	department shall:
128	(a) Create a secure, electronic, and online compassionate
129	use registry for the registration of physicians and patients as
130	provided under this section. The registry must be accessible to
131	law enforcement agencies and to a dispensing organization in
132	order to verify patient authorization for low-THC cannabis and
133	record the low-THC cannabis dispensed. The registry must prevent
134	an active registration of a patient by multiple physicians.
135	(b) Authorize the establishment of five dispensing
136	organizations to ensure reasonable statewide accessibility and
137	availability as necessary for patients registered in the
138	compassionate use registry and who are ordered low-THC cannabis
139	under this section, one in each of the following regions:
140	northwest Florida, northeast Florida, central Florida, southeast
141	Florida, and southwest Florida. The department shall develop an
142	application form and impose an initial application and biennial
	329511

Bill No. CS/CS/SB 1030 (2014)

Amendment No.

143	renewal fee that is sufficient to cover the costs of
144	administering this section. An applicant for approval as a
145	dispensing organization must be able to demonstrate:
146	1. The technical and technological ability to cultivate
147	and produce low-THC cannabis. The applicant must possess a valid
148	certificate of registration issued by the Department of
149	Agriculture and Consumer Services pursuant to s. 581.131 that is
150	issued for the cultivation of more than 400,000 plants, be
151	operated by a nurseryman as defined in s. 581.011, and have been
152	operated as a registered nursery in this state for at least 30
153	continuous years.
154	2. The ability to secure the premises, resources, and
155	personnel necessary to operate as a dispensing organization.
156	3. The ability to maintain accountability of all raw
157	materials, finished products, and any byproducts to prevent
158	diversion or unlawful access to or possession of these
159	substances.
160	4. An infrastructure reasonably located to dispense low-
161	THC cannabis to registered patients statewide or regionally as
162	determined by the department.
163	5. The financial ability to maintain operations for the
164	duration of the 2-year approval cycle, including the provision
165	of certified financials to the department. Upon approval, the
166	applicant must post a \$5 million performance bond.

329511

Bill No. CS/CS/SB 1030 (2014)

Amendment No.

AlleHulleHt No.
167 6. That all owners and managers have been fingerprinted
168 and have successfully passed a level 2 background screening
169 <u>pursuant to s. 435.04.</u>
170 <u>7. The employment of a medical director who is a physician</u>
171 licensed under chapter 458 or chapter 459 to supervise the
172 activities of the dispensing organization.
173 (c) Monitor physician registration and ordering of low-THC
174 cannabis for ordering practices that could facilitate unlawful
175 diversion or misuse of low-THC cannabis and take disciplinary
176 <u>action as indicated.</u>
(d) Adopt rules necessary to implement this section.
178 (6) DISPENSING ORGANIZATION.—An approved dispensing
179 organization shall maintain compliance with the criteria
180 demonstrated for selection and approval as a dispensing
181 organization under subsection (5) at all times. Before
182 dispensing low-THC cannabis to a qualified patient, the
183 dispensing organization shall verify that the patient has an
184 active registration in the compassionate use registry, the order
185 presented matches the order contents as recorded in the
186 registry, and the order has not already been filled. Upon
187 dispensing the low-THC cannabis, the dispensing organization
188 shall record in the registry the date, time, quantity, and form
189 of low-THC cannabis dispensed.
190 (7) EXCEPTIONS TO OTHER LAWS.—
191 (a) Notwithstanding s. 893.13, s. 893.135, s. 893.147, or
192 any other provision of law, but subject to the requirements of
329511

Bill No. CS/CS/SB 1030 (2014)

Amendment No.

193 this section, a qualified patient and the qualified patient's 194 legal representative may purchase and possess for the patient's 195 medical use up to the amount of low-THC cannabis ordered for the 196 patient. 197 (b) Notwithstanding s. 893.13, s. 893.135, s. 893.147, or 198 any other provision of law, but subject to the requirements of 199 this section, an approved dispensing organization and its 200 owners, managers, and employees may manufacture, possess, sell, 201 deliver, distribute, dispense, and lawfully dispose of reasonable quantities, as established by department rule, of 202 203 low-THC cannabis. For purposes of this subsection, the terms "manufacture," "possession," "deliver," "distribute," and 204 205 "dispense" have the same meanings as provided in s. 893.02. 206 (c) An approved dispensing organization and its owners, 207 managers, and employees are not subject to licensure or 208 regulation under chapter 465 for manufacturing, possessing, 209 selling, delivering, distributing, dispensing, or lawfully 210 disposing of reasonable quantities, as established by department 211 rule, of low-THC cannabis. 212 Section 3. Section 385.211, Florida Statutes, is created 213 to read: 214 385.211 Refractory and intractable epilepsy treatment and 215 research at recognized medical centers.-216 (1) As used in this section, the term "low-THC cannabis" means "low-THC cannabis" as defined in s. 381.986 that is 217

329511

Bill No. CS/CS/SB 1030 (2014)

Amendment No.

dispensed only from a dispensing organization as defined in s.
<u>381.986.</u>
(2) Notwithstanding chapter 893, medical centers
recognized pursuant to s. 381.925 may conduct research on
cannabidiol and low-THC cannabis. This research may include, but
is not limited to, the agricultural development, production,
clinical research, and use of liquid medical derivatives of
cannabidiol and low-THC cannabis for the treatment for
refractory or intractable epilepsy. The authority for recognized
medical centers to conduct this research is derived from 21
C.F.R. parts 312 and 316. Current state or privately obtained
research funds may be used to support the activities described
in this section.
Section 4. Section 385.212, Florida Statutes, is created
to read:
385.212 Powers and duties of the Department of Health;
Office of Compassionate Use
(1) The Department of Health shall establish an Office of
Compassionate Use under the direction of the Deputy State Health
Officer.
(2) The Office of Compassionate Use may enhance access to
investigational new drugs for Florida patients through approved
clinical treatment plans or studies. The Office of Compassionate
Use may:
(a) Create a network of state universities and medical
centers recognized pursuant to s. 381.925.
329511

Bill No. CS/CS/SB 1030 (2014)

Amendment No.

	Allendilent No.
244	(b) Make any necessary application to the United States
245	Food and Drug Administration or a pharmaceutical manufacturer to
246	facilitate enhanced access to compassionate use for Florida
247	patients.
248	(c) Enter into any agreements necessary to facilitate
249	enhanced access to compassionate use for Florida patients.
250	(3) The department may adopt rules necessary to implement
251	this section.
252	Section 5. Subsection (3) of section 893.02, Florida
253	Statutes, is amended to read:
254	893.02 DefinitionsThe following words and phrases as
255	used in this chapter shall have the following meanings, unless
256	the context otherwise requires:
257	(3) "Cannabis" means all parts of any plant of the genus
258	Cannabis, whether growing or not; the seeds thereof; the resin
259	extracted from any part of the plant; and every compound,
260	manufacture, salt, derivative, mixture, or preparation of the
261	plant or its seeds or resin. The term does not include "low-THC
262	cannabis," as defined in s. 381.986, if manufactured, possessed,
263	sold, purchased, delivered, distributed, or dispensed, in
264	conformance with s. 381.986.
265	Section 6. Section 1004.441, Florida Statutes, is created
266	to read:
267	1004.441 Refractory and intractable epilepsy treatment and
268	research
	20611
3	329511

Bill No. CS/CS/SB 1030 (2014)

Amendment No.

269	(1) As used in this section, the term "low-THC cannabis"
270	means "low-THC cannabis" as defined in s. 381.986 that is
271	dispensed only from a dispensing organization as defined in s.
272	<u>381.986.</u>
273	(2) Notwithstanding chapter 893, state universities with
274	both medical and agricultural research programs, including those
275	that have satellite campuses or research agreements with other
276	similar institutions, may conduct research on cannabidiol and
277	low-THC cannabis. This research may include, but is not limited
278	to, the agricultural development, production, clinical research,
279	and use of liquid medical derivatives of cannabidiol and low-THC
280	cannabis for the treatment for refractory or intractable
281	epilepsy. The authority for state universities to conduct this
282	research is derived from 21 C.F.R. parts 312 and 316. Current
283	state or privately obtained research funds may be used to
284	support the activities authorized by this section.
285	Section 7. (1) As used in this section, the term
286	"cannabidiol" means an extract from the cannabis plant that has
287	less than 0.8 percent tetrahydrocannabinol and the chemical
288	<pre>signature 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-</pre>
289	5-pentylbenzene-1,3-diol, or a derivative thereof, as determined
290	by the International Union of Pure and Applied Chemistry.
291	(2) For the 2014-2015 fiscal year, \$1 million in
292	nonrecurring general revenue is appropriated to the Department
293	of Health for the James and Esther King Biomedical Research
294	Program and shall be deposited into the Biomedical Research

l 329511

Bill No. CS/CS/SB 1030 (2014)

Amendment No.

	Americanerie no.
295	Trust Fund. These funds shall be reserved for research of
296	cannabidiol and its effect on intractable childhood epilepsy.
297	(3) Biomedical research funding for research of
298	cannabidiol and its effect on intractable childhood epilepsy
299	shall be awarded pursuant to s. 215.5602, Florida Statutes. An
300	application for such funding may be submitted by any research
301	university in the state that has obtained approval from the
302	United States Food and Drug Administration for an exploratory
303	investigational new drug study of cannabidiol and its effect on
304	intractable childhood epilepsy. For purposes of this section,
305	the Biomedical Research Advisory Council created under s.
306	215.5602, Florida Statutes, shall advise the State Surgeon
307	General as to the direction and scope of research of cannabidiol
308	and its effect on intractable childhood epilepsy and the award
309	of research funding.
310	Section 8. This act shall take effect upon becoming a law.
311	
312	
313	TITLE AMENDMENT
314	Remove everything before the enacting clause and insert:
315	A bill to be entitled
316	An act relating to cannabis; providing a short title;
317	creating s. 381.986, F.S.; defining terms; authorizing
318	specified physicians to order low-THC cannabis for use
319	by specified patients; providing conditions;
320	prohibiting specified acts by physicians or persons
	329511
3	

5/1/2014 7:57 PM

Page 13 of 15

Bill No. CS/CS/SB 1030 (2014)

Amendment No.

321 seeking low-THC cannabis; providing criminal 322 penalties; requiring physician education; providing 323 duties of the Department of Health; requiring the 324 department to create a compassionate use registry; 325 providing requirements for the registry; requiring the 326 department to authorize a specified number of 327 dispensing organizations; authorizing rulemaking; 328 providing requirements and duties for a dispensing 329 organization; providing exceptions to specified laws; 330 creating s. 385.211, F.S.; defining the term "low-THC 331 cannabis"; authorizing certain medical centers to 332 conduct research on cannabidiol and low-THC cannabis; 333 authorizing state or privately obtained research funds 334 to be used to support such research; creating s. 335 385.212, F.S.; requiring the department to establish 336 an Office of Compassionate Use; authorizing the office 337 to engage in specified activities; authorizing rulemaking; amending s. 893.02, F.S.; revising the 338 339 term "cannabis" as used in the Florida Comprehensive 340 Drug Abuse Prevention and Control Act and as 341 applicable to certain criminal offenses proscribing the sale, manufacture, delivery, possession, 342 343 dispensing, distribution, or purchase of cannabis, to 344 which penalties apply; creating s. 1004.441, F.S.; 345 defining the term "low-THC cannabis"; authorizing 346 state universities with both medical and agricultural

329511

Bill No. CS/CS/SB 1030 (2014)

Amendment No.

347	research programs to conduct specified research on
348	cannabidiol and low-THC cannabis; authorizing state or
349	privately obtained research funds to be used to
350	support such research; providing an appropriation to
351	the department for research of cannabidiol and its
352	effect on intractable childhood epilepsy; specifying
353	how biomedical research funding for research of
354	cannabidiol and its effect on intractable childhood
355	epilepsy shall be awarded; specifying who may apply
356	for such funding; providing an effective date.

329511